India has the potential to be one of the pharma superpowers of the future. The industry has evolved over the years from selling generic drugs in India, investing in research and development of niche drugs and selling in highly regulated international markets. Despite a challenging environment amidst talks of slowdown, pricing pressure and regulatory actions, the industry maintained a reasonable growth.
Further, the government’s move to make healthcare affordable to every citizen and ‘Pharma Vision 2020’ can only bring good tidings to the value chain.
In this launch edition of the quarterly publication, we bring you an in depth sectoral analysis of H1 2019 including export sales, R&D pipeline, tightening liquidity, among others besides talking about the impact of regulatory announcements on the sector and the challenges that might beckon.